The research results of the primary liver cancer of Wuhan University People's Hospital won the first prize of 2021 Hubei Science and Technology Progress

Wuhan Evening News, June 25 (Cao Dadong) On June 25, accelerated the construction of the scientific and technological innovation center with national influence and the Hubei Provincial Science and Technology Innovation Conference in Wuhan Hongshan Auditorium. Hospital) The "Mechanism and Precision Treatment of Primary liver cancer and its precise treatment" project presided over by Professor Xu Ximing, Department of Tumor III, and won the first prize of Hubei Science and Technology Progress.

Professor Xu Ximing.

Hepatocellular Carcinoma (HCC) is ranked fourth of all malignant tumors in China and ranked second in the mortality rate. In recent years, with the development of technical means such as images, biochemistry, and pathology, the early diagnosis and treatment of liver cancer have made great progress, and the survival rate has also increased significantly. Reducing the incidence of HCC and mortality and improving its treatment efficacy has become a clinical problem that is urgent to solve.

Professor Xu Ximing.

In the past ten years, Professor Xu Ximing led the research team of the Department of Tumor III of the Department of Tumor III of the People's Hospital of Wuhan University to carry out the basis and clinical research of the pathogenesis of hepatitis B -related liver cancer in response to the pathogenesis of primary liver cancer and accurate treatment. Treatment of creative establishment of a "targeted+" treatment system, and accurate prediction model of liver cancer.

The project has found the positive feedback mechanism of primary liver cell carcinoma and hepatitis B virus, and establishes anti -hepatitis B virus to block the strategies for positive feedback to promote the development of liver cancer in Cthrc1, PLA2G2A, CTBP2, KIF4A and other factors. The project also summarizes a set of liver cancer "targeted+" treatment systems such as targeted therapy/radiotherapy/radiotherapy/radio frequency ablation/liver artery embolism, targeted therapy combined immunotherapy/chemotherapy drugs, which meets the current Multi -disciplinary diagnosis and treatment models have obvious clinical advantages. In addition, the project has discovered multiple new targets, and establishes a number of precision prediction models that are closely related to the onset of primary liver cancer, curative effect and prognosis, and significantly improve the treatment effect of patients.

In the past ten years, through various forms such as sending guidance, visiting lectures, visiting and exchanges, and receiving training and training, this research results have been continuously promoted and applied to effectively improve the precise treatment of patients with primary liver cancer. It has achieved good social benefits. In addition, the research results of the project have strongly promoted the scientific and technological progress in the field of "targeted+" precision treatment in primary liver cancer, and improved the international influence of primary liver cell cancer diagnosis and treatment in my country.

[Edit: Yu Lina]

- END -